Ruxolitinib acts as a selective inhibitor of CaMKII-γ to impede the progression of Bortezomib-resistant multiple myeloma through AMPK-ULK1 axis-mediated autophagy pathwayMingdi Wang, Chaofeng Zhang|Research Square|2025Cited by 0